| Document Date: 2015-04-29 11:31:59
Open Document File Size: 146,65 KBShare Result on Facebook
IndustryTerm human fibrinogen products / fibrinogen products / inhibitor products / human plasma fibrinogen products / manufacturing steps / treatment of coagulation disorders / rubber / chemical / medicinal products / / MedicalCondition hepatitis A / isolated deficiency / Manifest thrombosis / anaphylactic shock / HIV / extensive injuries / disseminated intravascular coagulation / HBV / coagulation disorders / especially promyelocytic leukaemia / shock / chronic / Parvovirus B19 infection / defibrination syndrome / hepatitis C / hepatitis B / acute leukaemia / HCV / congenital deficiency / Contraindications Hypersensitivity / fibrinogen deficiency / myocardial infarction / acquired fibrinogen deficiency / non-enveloped hepatitis A / urticaria / fetal infection / disorder / pulmonary embolism / coronary heart disease / infection / deficiency / thrombosis / liver disease / infections / rash / correction cirrhosis / sepsis / disorders / tumours / / MedicalTreatment vaccination / Intravenous infusion / / Organization European Union / / Person Fibrinogen Rev / / Position physician / RT / General / / Product Cl / sodium chloride / / RadioStation Core / / Technology pharmacokinetics / antibodies / /
SocialTag |
COMPANY CORE DATA SHEET – CCDS (EDS/CORE/ENGLISH) HAEMOCOMPLETTAN® P 1G/2G Rev.: 22-MAYcorrection Supersedes previous versions Rev.: 30-AUGAdaptation to EU Core-SPC Fibrinogen Rev.: 23-SEP